摘要
目的探讨帕罗西汀联合丙戊酸镁治疗脑梗塞后抑郁的临床疗效和安全性。方法将85例脑梗塞后抑郁患者随机分为两组，研究组43例，对照组42例，两组患者在神经内科常规治疗和康复治疗的基础上，研究组口服帕罗西汀联合丙戊酸镁治疗，对照组单用帕罗西汀治疗，观察8w。于治疗前及治疗2w、4w、6w、8w末采用汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果两组治疗2w末起，汉密顿抑郁量表总分均较治疗前显著下降（P〈0．01），减分率随着治疗时间的延续均呈持续性升高；同期研究组总分均较对照组下降显著（P〈0．05或0．01）；两组不良反应均轻微，主要表现为恶心、便秘等。结论帕罗西汀联合丙戊酸镁治疗脑梗塞后抑郁较单用帕罗西汀治疗起效快，疗效更显著，不良反应轻微，安全性高。
Objective To explore the clinical efficacy and safety of paroxetine plus magnessium valproate in the treatment of depression after cerebral infarction （DACI）. Methods 85 DACI patients were randomly divided into research（n=43） and control group（n=42）, on the basis of conventional therapy and convalescent care of neurology department for both groups the research took orally paroxetine plus magnessium valproate and the control group did paroxetine only for 8 weeks. Before treatment and at the end of the 2nd, 4th, 6th and 8th week, clinical efficacies were assessed with Hanmihon Depression Rating Scale（HAMD） and adverse reactions with the Treatment Emergent Symptom Scale（TESS）. Results Since the end of the 2nd week, the total scores of the HAMD of both groups lowered more significantly compared with pretreatment（P〈0.01） and score reducing rates increased continously with treatment; the total score in the corresponding time period lowered more significantly in the research than in the control group（P〈0.05 or 0.01） ; adverse reactions of both groups were mild and mainly nausea, constipation and so on. Conclusion Paroxetine combined with magnesium valproate takes effect faster, has an more evident effect, mild adverse reactions and higher safety compared with single paroxetine in the treatment of depression after cerebral infarction.
出处
《临床心身疾病杂志》
CAS
2009年第6期483-484,共2页
Journal of Clinical Psychosomatic Diseases
